Sunfox Technologies, a health-tech startup, has secured ₹15 crore in a pre-Series A funding round, led by Venture Catalysts, an integrated incubator and accelerator.
The funding round also saw participation from Finvolve through the IA Growth Opportunities Fund I, Brew Opportunities Fund, Universal Group, and RP Singhvi Group.
With this new capital, Sunfox is set for rapid expansion in India and globally, focusing on scaling its flagship innovation, Spandan. Spandan is a smartphone-based portable ECG device that provides 12-lead ECG readings, to detect heart attacks and monitor cardiac health in real-time.
The company had previously secured a ₹5 crore investment from United States Agency For International Development (USAID) through SAMRIDH Health and LetsVenture, bringing the total raised in this round to ₹20 crore.
Apoorva Ranjan Sharma, Co-founder, and Managing Director of Venture Catalysts said, “Sunfox represents the future of cardiac care. We are proud partners in their journey and are excited to see them reach new heights with Spandan. Their mission to make heart health accessible globally is truly inspiring, and we believe they are poised to reshape the healthcare landscape.”
Rajat Jain, CEO of Sunfox said, “This capital injection will enable us to scale rapidly, both in India and internationally. It will fuel our growth and bring Spandan into homes and clinics worldwide. We envision a future where heart attacks are as preventable as fevers, with Spandan becoming as ubiquitous as a household thermometer.”
Sunfox, a Dehradun-based, has established an advanced in-house R&D and manufacturing facility in the hilly state, capturing global attention from prestigious institutions such as Oxford and Wharton.
Sunfox first gained widespread recognition when all five sharks—Namita Thapar, Peyush Bansal, Anupam Mittal, Vineeta Singh, and Ghazal Alagh—invested during its Shark Tank India debut.
